Collaboration With Merck’s Protease Inhibitor The Fourth HCV Tie-Up For Bristol’s Daclatasvir

Merck and Bristol will run a Phase II trial testing daclatasvir, an NS5A replication complex inhibitor, in tandem with MK-5172, Merck’s potentially pan-genotypic protease inhibitor in a non-exclusive partnership in hepatitis C. It’s the second such deal Bristol has signed this month, following an April 5 agreement with Vertex.